Analysts Issue Forecasts for Krystal Biotech Q2 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Research analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Krystal Biotech in a research report issued to clients and investors on Wednesday, February 18th. HC Wainwright analyst J. Pantginis expects that the company will earn $1.37 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $310.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech’s Q3 2026 earnings at $1.50 EPS, Q4 2026 earnings at $1.68 EPS, FY2026 earnings at $5.78 EPS, FY2027 earnings at $6.52 EPS and FY2028 earnings at $11.52 EPS.

KRYS has been the subject of a number of other reports. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. The Goldman Sachs Group boosted their price objective on Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Citigroup boosted their price objective on shares of Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Bank of America raised their target price on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $318.75.

Krystal Biotech Stock Performance

Shares of KRYS opened at $261.80 on Friday. The business’s fifty day moving average price is $265.50 and its two-hundred day moving average price is $209.66. The firm has a market capitalization of $7.65 billion, a price-to-earnings ratio of 38.22 and a beta of 0.49. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The business had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million.

Institutional Investors Weigh In On Krystal Biotech

Several hedge funds have recently bought and sold shares of KRYS. Hantz Financial Services Inc. raised its stake in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after purchasing an additional 179 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares during the period. AdvisorNet Financial Inc purchased a new position in shares of Krystal Biotech in the third quarter worth approximately $30,000. Salomon & Ludwin LLC bought a new stake in Krystal Biotech during the third quarter valued at approximately $33,000. Finally, First Horizon Advisors Inc. grew its position in Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock valued at $34,000 after buying an additional 166 shares during the period. Institutional investors own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the sale, the insider owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Kathryn Romano sold 12,500 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 13.70% of the company’s stock.

Key Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: KRYS reported a quarterly earnings beat (Feb. 17) — EPS and revenue topped consensus, which drove an initial gap up in shares after the print. That strong operational result supports higher near-term momentum for the stock. Krystal Biotech Shares Gap Up After Earnings Beat
• Positive Sentiment: Chardan Capital raised its price target to $323, signaling continued institutional enthusiasm from some brokers and providing upside narrative against the recent pullback. Chardan Boosts KRYS Price Target to $323
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $310 target, indicating that at least one major analyst house still views medium-term upside despite model revisions. HC Wainwright Coverage
• Neutral Sentiment: Analyst commentary pieces are reframing KRYS after recent data and target resets — these articles summarize shifting expectations around the Vyjuvek commercial ramp and pipeline positioning, useful context but not direct catalysts. Why Analysts See KRYS Story Shifting Reassessing KRYS After Rally and Pipeline Focus
• Neutral Sentiment: Reported short-interest figures appear to be erroneous/zero (entries show 0 shares and 0.0 days-to-cover). Because the data is clearly inconsistent, it is unlikely to be a reliable trading signal today.
• Negative Sentiment: HC Wainwright materially trimmed EPS forecasts across FY2026–FY2028 (e.g., FY2026 cut from ~$7.41 to $5.78 and FY2027 from ~$10.21 to $6.52), reducing modeled growth and future earnings upside — a clear negative for valuation expectations even though the firm kept its Buy rating. HC Wainwright Estimates and Revisions

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.